25-year-old, Fetal Ultrasound

The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.

In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.

Reportedly developed on over 90,000 ultrasound exams, the BrightHeart AI software identifies suspicious findings suggestive of congenital heart defects through AI-powered evaluation of fetal heart morphology.

Dr. Laurence Klotz discusses micro-ultrasound as a faster, less invasive, more cost-effective screening strategy compared to mpMRI in this podcast.

The Sonire Therapeutics ultrasound system is currently being studied for the treatment of patients with unresectable pancreatic cancer refractory or intolerant to first-line chemotherapy.

The new ultrasound platform reportedly offers a combination of enhanced imaging and AI-enabled tools to facilitate improved workflow efficiency.